Skip to content
10-Q

Quarterly Report

PROTO SCRIPT PHARMACEUTICAL CORP

0001078782-17-000022

← back to feed
Filed
Jan 6, 2017 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2016 · Dec 30, 2016 330.48M sh
Operating Cash Flow Q3 2016 · Sep 30, 2016 $3.22K
Operating Cash Flow Q3 2016 · Sep 30, 2015 $41.62K
Stockholders Equity Q3 2016 · Sep 30, 2016 −$22.13K
Stockholders Equity Q3 2016 · Dec 31, 2015 $62.24K
Current Liabilities Q3 2016 · Sep 30, 2016 $291.25K
Current Liabilities Q3 2016 · Dec 31, 2015 $136.7K
Current Assets Q3 2016 · Sep 30, 2016 $254.26K
Current Assets Q3 2016 · Dec 31, 2015 $183.5K
Total Assets Q3 2016 · Sep 30, 2016 $269.13K
Total Assets Q3 2016 · Dec 31, 2015 $198.94K
Capex Q3 2016 · Sep 30, 2015 $3.36K
Sga Expense Q3 2016 · Sep 30, 2015 $173.8K
Sga Expense Q3 2016 · Sep 30, 2015 $582.37K
Net Income Q3 2016 · Sep 30, 2015 −$57.74K
Net Income Q3 2016 · Sep 30, 2015 −$76.42K
Gross Profit Q3 2016 · Sep 30, 2015 $116.05K
Gross Profit Q3 2016 · Sep 30, 2015 $505.95K
Cost Of Revenue Q3 2016 · Sep 30, 2015 $6.22K
Cost Of Revenue Q3 2016 · Sep 30, 2015 $161.75K
Cash And Equivalents Q3 2016 · Dec 31, 2014 $31.15K